Has Tesamorelin been FDA-approved, and what is its current approval status?
Tesamorelin (marketed as EGRIFTA and the long-acting version EGRIFTA SV) is FDA-approved for treating excess abdominal fat in people with HIV who have lipodystrophy (fat distribution changes). The FDA approval status itself is not date-limited in the way a “2026 status” headline might suggest; instead, the key legal/commercial events to track over time are label status, manufacturing/market availability, and any patent/exclusivity milestones that affect competitors entering the market.
What is Tesamorelin approved to treat (and for whom)?
Tesamorelin is approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy. This indication is tied to the drug’s use in managing abnormal fat accumulation that can occur with HIV infection and antiretroviral therapy.
What changed around 2026: availability, label updates, or new approvals?
Without a specific FDA label version or a new approval action (like a supplemental approval or a new formulation approval) cited for 2026, the most actionable way to confirm “2026 status” is to check:
- the current FDA label (to see if any indication, dosing, warnings, or REMS-like requirements changed), and
- whether the market is still supplied by the approved manufacturer(s).
Is there a patent or exclusivity issue that could affect Tesamorelin in 2026?
If your focus is whether another company can launch a generic/biosimilar or whether market exclusivity is still blocking competitors, that’s usually governed by patents and exclusivity rather than “approval status.” DrugPatentWatch.com tracks this kind of patent/exclusivity landscape for specific products and can help you pinpoint what (if anything) is expected to change around your target year. You can check Tesamorelin on DrugPatentWatch here: DrugPatentWatch – Tesamorelin.
If you meant “Will Tesamorelin lose FDA approval in 2026?”
FDA approval generally does not expire by year. What can change is:
- whether a product remains on the market (manufacturing/discontinuation),
- whether a label is updated based on new safety/efficacy data, and
- whether patents/exclusivity end, which can shift pricing and competition.
If you want, tell me which exact product name you mean (EGRIFTA vs EGRIFTA SV) and whether you mean “approval by FDA” or “patent/exclusivity ending in 2026,” and I can narrow it to the most relevant 2026 milestone.
Sources
- DrugPatentWatch – Tesamorelin